1. Home
  2. RNXT vs IRD Comparison

RNXT vs IRD Comparison

Compare RNXT & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • IRD
  • Stock Information
  • Founded
  • RNXT 2012
  • IRD 2018
  • Country
  • RNXT United States
  • IRD United States
  • Employees
  • RNXT N/A
  • IRD N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • RNXT Health Care
  • IRD
  • Exchange
  • RNXT Nasdaq
  • IRD NYSE
  • Market Cap
  • RNXT 31.6M
  • IRD 36.0M
  • IPO Year
  • RNXT 2021
  • IRD N/A
  • Fundamental
  • Price
  • RNXT $1.04
  • IRD $1.13
  • Analyst Decision
  • RNXT Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • RNXT 1
  • IRD 1
  • Target Price
  • RNXT $9.00
  • IRD $8.00
  • AVG Volume (30 Days)
  • RNXT 242.7K
  • IRD 144.3K
  • Earning Date
  • RNXT 03-31-2025
  • IRD 02-24-2025
  • Dividend Yield
  • RNXT N/A
  • IRD N/A
  • EPS Growth
  • RNXT N/A
  • IRD N/A
  • EPS
  • RNXT N/A
  • IRD N/A
  • Revenue
  • RNXT N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • RNXT N/A
  • IRD N/A
  • Revenue Next Year
  • RNXT N/A
  • IRD $29.37
  • P/E Ratio
  • RNXT N/A
  • IRD N/A
  • Revenue Growth
  • RNXT N/A
  • IRD N/A
  • 52 Week Low
  • RNXT $0.77
  • IRD $0.81
  • 52 Week High
  • RNXT $1.86
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 32.70
  • IRD N/A
  • Support Level
  • RNXT $1.00
  • IRD N/A
  • Resistance Level
  • RNXT $1.18
  • IRD N/A
  • Average True Range (ATR)
  • RNXT 0.10
  • IRD 0.00
  • MACD
  • RNXT -0.04
  • IRD 0.00
  • Stochastic Oscillator
  • RNXT 8.00
  • IRD 0.00

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: